Mod­er­na CEO shares bold new vi­sion: 15 new prod­ucts and 50 new clin­i­cal can­di­dates in five years

If there’s one thing that Mod­er­na CEO Stéphane Ban­cel wants to make abun­dant­ly clear, it’s that his com­pa­ny and its mR­NA tech­nol­o­gy are not a one-hit won­der.

On Wednes­day morn­ing, Mod­er­na an­nounced its in­ten­tions to launch up to 15 new prod­ucts and ad­vance up to 50 mR­NA med­i­cines in­to clin­i­cal tri­als over the next five years — an au­da­cious goal for a biotech best known for its on­ly prod­uct: a Covid-19 vac­cine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER